NCT06312670 - Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 16, 2024

Primary Completion Date

January 9, 2025

Study Completion Date

January 9, 2025

Conditions

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Prostate CancerProstate Adenocarcinoma

Interventions

DRUG

EPI-7386

600 mg orally administered twice daily

DRUG

Enzalutamide

160 mg administered orally once daily, with or without food

DRUG

Androgen Deprivation Therapy (ADT)

LHRH agonist/antagonist or orchiectomy

Trial Locations (2)

University Hospitals Cleveland Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland